Free Newsletter
Genetic breakthrough offers new target for obesity, diabetes
A drug that targets a newly discovered genetic master switch which controls the formation of fat tissue would be able to prevent obesity as well as a host of ailments like diabetes and cardiovascular diseases, says a team of researchers at the University of Central Florida.
Pappachan Kolattukudy, dean of the university's Burnett School of Biomedical Sciences, says that the MCPIP gene is the key to controlling obesity, adding that until now researchers have been focused on a different protein. And Kolattukudy adds that MCPIP is an ideal target for any developer looking to thwart an epidemic of Type 2 diabetes.
"Our research has shown that MCPIP is a regulator of fat cell formation and blood vessel formation that feeds the growing fat tissue," said the dean. "Therefore, a drug that can shut down its function can prevent obesity and the major inflammatory diseases resulting from obesity, including diabetes and cardiovascular diseases."
- see the press release
- check out the UPI report
Related Articles:
'Obesity gene' could be key to new therapy
Scripps Research team finds new obesity target
Genetic tinkering creates obesity-resistant mice
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: